免責聲明 | 香港 | | | --- | --- | | 代扣所得稅信息 | | | 股息所涉及的代扣所得稅 | 不適用 | | 發行人所發行上市權證/可轉換債券的相關信息 | | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 可就部分股息行使貨幣選擇權只適用於香港中央結算(代理人)有限公司。 | | | 發行人董事 | | | 於本公告日期，董事會成員包括執行董事于海先生、張闖先生、王躍興先生及吳新春先生；非執行董事房昕先生；獨立非執行董事 | | | 胡定旭先生、傅廷美先生、周鵬先生及羅詠詩女士。 | | 第 2 頁 共 2 頁 v 1.1.1 EF002 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | --- | --- | | | 股票發行人現金股息（可選擇貨幣）公告 | | 發行人名稱 | 華潤醫療控股有限公司 | | 股份代號 | 01515 | | 多櫃檯股份代號及貨幣 | 不適用 | | ...

Financial Performance - Total revenue for the year ending December 31, 2025, is projected to be RMB 9,175,645, a decrease of 6.9% from RMB 9,854,790 in 2024[2] - Net profit attributable to the company for the year is expected to be RMB 495,944, down 12.3% from RMB 565,875 in 2024[3] - Basic earnings per share (EPS) is projected to be RMB 0.39, a decrease from RMB 0.45 in the previous year[3] - Gross profit for the year is expected to be RMB 1,440,773, down from RMB 1,809,826 in 2024, indicating a decline in gross margin[3] - Total comprehensive income for the year is projected to be RMB 568,589, down from RMB 639,267 in 2024[5] - Other income is expected to rise to RMB 313,535, compared to RMB 140,991 in the previous year[3] - The projected tax expense for the year is RMB 191,567, compared to RMB 166,923 in 2024, indicating a potential increase in tax liabilities[3] - The pre-tax profit for the year ending December 31, 2025, is RMB 747,665, and for 2024, it is RMB 838,670[20][21] - The total tax expense for the year 2025 is RMB 191,567,000, compared to RMB 166,923,000 in 2024, reflecting an increase of approximately 14.7%[33] Dividends - The company plans to maintain an interim dividend of RMB 0.05 per share and a proposed final dividend of RMB 0.084 per share, slightly increasing from RMB 0.082 in 2024[2] - The proposed final dividend for 2025 is RMB 8.4 cents per share, up from RMB 8.2 cents in 2024, indicating a growth of 2.4%[33] - The total dividend for the fiscal year 2025 is expected to be approximately RMB 174 million, including a mid-term dividend of RMB 65 million and the proposed final dividend of RMB 109 million[77] - The company's dividend policy is subject to review and is contingent upon its financial condition, operational performance, and capital requirements[79] Assets and Liabilities - Total current assets amounted to RMB 10,061,873 thousand in 2025, slightly down from RMB 10,079,012 thousand in 2024, representing a decrease of approximately 0.2%[6] - Total liabilities decreased to RMB 2,852,603 thousand in 2025, down from RMB 3,239,138 thousand in 2024, representing a reduction of approximately 11.9%[6] - The company’s total equity increased to RMB 7,905 thousand in 2025, compared to RMB 4,605 thousand in 2024, reflecting a growth of 71.5%[6] - The total current liabilities for the group amounted to RMB 4,499,386 thousand as of December 31, 2025[7] - The group reported a total asset value of RMB 8,818,764 thousand as of December 31, 2025[7] - The group’s total liabilities amounted to RMB 4,429,931 thousand as of December 31, 2024[7] - The group’s non-current liabilities totaled RMB 596,910 thousand as of December 31, 2024[7] Operational Performance - The group operates primarily in providing comprehensive medical services and hospital management services in mainland China[8] - The group’s segments include hospital operations and other services, which encompass management services for affiliated hospitals and supply chain services[16] - The hospital business segment reported revenue of RMB 8.675 billion, a decrease of 5.5% year-on-year[46] - The total number of medical visits for self-owned hospitals was 10,325,639[45] - The company aims to enhance quality and efficiency to mitigate the impact of declining average revenue on hospital business profits[47] - The company aims to increase emergency visit numbers by 5.6% in the second half of 2025 compared to the same period in 2024, while inpatient visits are expected to decrease by 1.4%[48] Financial Management - The company anticipates a decrease in finance costs to RMB 49,558 from RMB 75,275 in 2024, reflecting improved financial management[3] - The company reported a financial expense of RMB (15,967) for 2025 and RMB (18,960) for 2024[20][21] - The company experienced a net loss from financial and contractual assets of RMB (22,511) in 2025 and a net loss of RMB (5,704) in 2024[20][21] - The company has not used any financial instruments to hedge currency risks, managing such risks through close monitoring of foreign exchange rate fluctuations[59] Legal Matters - The company has been involved in ongoing litigation regarding the Yanhua IoT Agreement since 2019[89] - The Beijing Second Intermediate People's Court ruled that Yanhua Hospital must pay RMB 3.0575 million in annual return payments and late fees[90] - A new lawsuit was filed in June 2025 to seek the termination of the Yanhua IoT Agreement and related compensation payments[91] Employee and Governance - The company has implemented a mandatory contribution retirement benefit plan in Hong Kong, calculated as a percentage of employees' basic salaries[75] - Employees in mainland China must participate in a central pension plan, with contributions deducted from the profit and loss statement[76] - The company emphasizes effective communication and regular meetings to foster collaboration between management and employees[75] - The company has adhered to all applicable corporate governance codes during the reporting period, except for a temporary deviation regarding the roles of Chairman and CEO from June 19, 2025, to November 6, 2025[82] Future Outlook - The company aims to enhance its role in the regional healthcare system and strengthen its operational advantages through refined cost management and collaboration with high-level hospitals[70] - The healthcare industry is transitioning from a disease-centered approach to a health-centered approach, presenting long-term growth potential[69] - The company plans to provide comprehensive health services through a "hospital-to-enterprise-to-home" model, optimizing its health management services[71]

非執行董事 房昕 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 董事名單及其角色和職能 華潤醫療控股有限公司的董事會（「董事會」）成員載列如下： 執行董事 于海， 董事長 張闖， 總裁 王躍興 吳新春， 副總裁 附註： C 有關董事委員會之主席 M 有關董事委員會之成員 中國，2026年3月11日 獨立非執行董事 胡定旭 傅廷美 周鵬 羅詠詩 董事會設立三個委員會，即審核委員會、提名委員會及薪酬委員會。各董事會成 員在該等委員會所擔任的職位載列如下。 | 董事 | 委員會 | 審核委員會 | 提名委員會 | 薪酬委員會 | | --- | --- | --- | --- | --- | | 于海 | | | C | | | 張闖 | | | | | | 王躍興 | | | | | | 吳新春 | | | | | | 房昕 | | | | M | | 胡定旭 | | | M | C | | 傅廷美 | | C | | M | | 周鵬 | | M | | | | 羅詠詩 | | M | M | | ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 董事會藉此衷心感謝葛女士於任內作為非執行董事及薪酬委員會委員期間對本集 團作出的寶貴貢獻。 – 1 – 非執行董事及薪酬委員會委員之委任 董事會欣然宣佈，房昕先生（「房先生」）獲委任為非執行董事及薪酬委員會委員， 自2026年3月11日起生效。 房先生的履歷詳情如下： （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 非執行董事及董事會下屬專門委員會組成變更 董事會謹此宣佈，自2026年3月11 日起：(1)葛路女士退任非執行董事及薪酬委 員會委員；及(2)房昕先生獲委任為非執行董事及薪酬委員會委員。 非執行董事及薪酬委員會委員之退任 華 潤 醫 療 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）之 董 事（「 董 事」）會（「董事會」）謹此宣佈，葛路女士（「葛女士」）已知會 ...

董事會會議日期 華潤醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）茲通告謹定於2026 年 3 月 24 日（ 星 期 二 ）舉 行 董 事 會 會 議 ， 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 2025 年12 月31 日止年度 的綜合 全年業績 及其發 佈、考慮 派發末 期股息之 建議（ 如 有 ），以及處理其他事項。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 華潤醫療控股有限公司 董事長 于海 中國，2026年3月9日 於本公告日期，董事會成員包括執行董事于海先生、張闖先生、王躍興先生及吳 新春先生；非執行董事葛路女士；獨立非執行董事胡定旭先生、傅廷美先生、周 鵬先生及羅詠詩女士。 承董事會命 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華潤醫療控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01515 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,040,000,000 | HKD | | 0.00025 | HKD | | 760,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,040,000,000 | HKD | | 0.00025 | HKD | | 760,000 | 本月底法定/註冊股本 ...

Core Viewpoint - China Resources Medical (01515) expects a decline in profit attributable to shareholders for the year ending December 31, 2025, estimated between RMB 467 million to RMB 516 million, representing a decrease of approximately 17.5% to 8.9% compared to the profit of RMB 566 million for the year ending December 31, 2024 [1] Summary by Relevant Sections - **Profit Forecast** - The company anticipates a profit attributable to shareholders of approximately RMB 467 million to RMB 516 million for the fiscal year ending December 31, 2025 [1] - This represents a decline of about 17.5% to 8.9% compared to the previous year's profit of RMB 566 million [1] - **Adjusted Profit Analysis** - Excluding a one-time receipt of approximately RMB 210 million related to the Yan Hua IOT agreement and corresponding corporate income tax, the profit attributable to shareholders is expected to decline by approximately 43.5% to 37.6% compared to the 2024 fiscal year [1] - The decline in profit is less severe than the 57.4% drop observed in the first half of 2025 compared to the same period in 2024, narrowing by approximately 13.9 to 19.8 percentage points [1] - **Reasons for Profit Decline** - The primary reason for the decrease in profit is attributed to a reduction in average medical insurance expenses leading to decreased operating profits for member medical institutions [1] - Additionally, the scale of the company's IOT (Investment-Operation-Transfer model) business has contracted, further impacting profitability [1]

Core Viewpoint - China Resources Medical (01515) expects a decline in profit attributable to shareholders for the year ending December 31, 2025, with estimates ranging from RMB 467 million to RMB 516 million, representing a decrease of approximately 17.5% to 8.9% compared to the estimated profit of RMB 566 million for the year ending December 31, 2024 [1] Financial Performance - The profit attributable to shareholders is expected to decrease by approximately 43.5% to 37.6% when excluding a one-time compensation of about RMB 210 million related to the Yan Hua IOT agreement and corresponding corporate income tax [1] - The decline in profit is less severe compared to a 57.4% drop in profit attributable to shareholders in the first half of 2025, indicating a narrowing of the decline by approximately 13.9 to 19.8 percentage points [1] Operational Challenges - The primary reason for the decline in profit is attributed to a decrease in average medical expenses under the healthcare insurance system, which has negatively impacted the operating profits of member medical institutions [1] - Additionally, the scale of the company's IOT (Investment-Operation-Transfer) business has contracted, further contributing to the decline in profitability [1]

Group 1 - The company announced that Ms. Yang Min will resign as Executive Director and Chief Financial Officer effective February 27, 2026 [1] - Mr. Wang Yuexing has been appointed as Executive Director [1]

Group 1 - The core announcement is that Ms. Yang Min will resign as Executive Director and Chief Financial Officer of China Resources Medical (01515) effective February 27, 2026 [1] - Mr. Wang Yuexing has been appointed as Executive Director of the company [1]